U.S. Physical Therapy delivered a quarter that surpassed Wall Street’s expectations, with management attributing the outperformance to strong execution of its hospital partnership strategy and sustained volume growth. CEO Chris Reading credited the company’s ability to maintain record patient visits per clinic, even through a seasonally softer period, as a key factor. The integration of Metro N.Y. and Gulf Coast hospital affiliations led to a significant increase in hospital-based revenue, which in turn drove a record net rate per visit. Management also pointed to improved productivity at mature clinics and notable gains in its industrial injury prevention business, while acknowledging elevated self-insured health costs as a margin headwind.
Is now the time to buy USPH? Find out in our full research report (it’s free for active Edge members).
U.S. Physical Therapy (USPH) Q3 2026 highlights:
- Revenue $220.6 million vs S&P analysts’ estimates of $214.3 million (11.9% year-on-year growth, 2.9% beat)
- Adjusted EPS $0.80 vs S&P analysts’ estimates of $0.73 (10.3% beat)
- Adjusted EBITDA $27.78 million vs analyst estimates of $26.55 million (12.6% margin, 4.6% beat)
- EBITDA guidance $104 million at the midpoint for the full year, in line with analyst expectations
- Operating margin 11.5%, down from 12.8% in the same quarter last year
- Sales volumes rose 8.3% year on year (18% in the same quarter last year)
- Market capitalization $1.45 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from U.S. Physical Therapy’s Q3 earnings call
-
Joanna Gajuk (Bank of America) questioned the sequential growth potential from hospital affiliations in Q4. CEO Chris Reading confirmed Q4 will be the first full quarter with both partnerships fully integrated, but did not provide a specific growth estimate.
-
Jack Slevin (Jefferies) asked about the drivers behind robust volume growth and whether additional hospital partnerships are likely soon. Reading emphasized broad-based demand and ongoing discussions with several hospital systems, while cautioning that new partnerships may take time to close.
-
Mike Petusky (Barrington Research) inquired about hospital partnership EBITDA contributions and the likelihood of exceeding previous incremental EBITDA estimates. Reading stated that performance is trending ahead of initial expectations, particularly in Metro N.Y., but was not ready to provide updated figures.
-
Larry Solow (CJS Securities) sought detail on margin expansion potential, especially as hospital clinics ramp. CFO Nchacha Etta explained that margin gains are expected as volumes increase and cost controls take hold but warned that elevated employee benefit costs remain a near-term risk.
-
Constantine Davides (Citizens) probed the timeline and magnitude of cost savings from workforce reductions and revenue cycle initiatives. COO Eric Williams described ongoing efforts to centralize billing and reduce administrative staffing, with some benefits realized in Q3 and more expected in coming quarters.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will closely monitor (1) the pace of hospital clinic conversions and affiliated revenue growth, (2) sustained progress on labor and discretionary expense reductions to offset healthcare cost inflation, and (3) early impacts from regulatory changes such as the IPCI modifier phase-out. Execution on centralized billing initiatives and new clinic acquisitions will also serve as key indicators of management’s ability to deliver margin improvements.
U.S. Physical Therapy currently trades at $95.70, up from $89.52 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
High-quality stocks for all market conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
